

PATENTED.MEDICINE
PRICES REVIEW BOARD

2005 APR 14 PM 3 07

CONSEIL D'EXAMEN
DU PRIX DES
MEDICAMENTS BREVETES



GlaxoSmithKline Inc.

Paul N. Lucas
President & Chief Executive Officer

7333 Mississauga Road, North
Mississauga, Ontario
Canada L5N 6L4

Tel. 905 819 3030
Fax. 905 819 3097

paul.n.lucas@gsk.com

April 14, 2005

050402

Patented Medicines Prices Review Board
Box L40
Standard Life Centre
333 Laurier Avenue West
14th Floor
Ottawa, Ontario
K1P 1C1

3225-3-13

Dear Sir:

I am writing to express my concerns on the proposed amendments to the Patented Medicines Regulations and to show my support for the submission that was sent to you by Rx&D.

The regulatory environment in Canada is already restrictive relative to other free markets. Submission of data 60 days prior to first sale, advanced notice of price increase and the provision of pricing data and sales information incremental to what is currently provided would unnecessarily add bureaucratic hurdles to an already cumbersome process. These requirements, if approved, would also create an opportunity for wholesalers, distributors and pharmacies to profit inappropriately from advanced notice of price changes.

The PMPRB already has a mandate. The proposed changes would increase regulatory burden on patentees, would add bureaucracy that would further stifle investment in Canada and would not add any value to the health or economic well-being of Canadians. Therefore, without any demonstrable benefits to Canadians, I cannot and do not support the proposed amendments.

Sincerely,

Paul N. Lucas
President and C.E.O.

PNL/seh